Dengue-endemic countries have an increasingly strong voice on the world stage; they should use it to redefine how dengue is viewed by the rest of the world. The consensus at the meeting was that while dengue is currently a major global public health problem, with the introduction

of an effective vaccine it is a disease that can be controlled. It will be crucial to change the perception of dengue in non-endemic countries, where much of the funding may need to originate, and publicise the full burden and cost of dengue. The prospect of a vaccine for dengue being available in the near future is encouraging, but in order to ensure that it is introduced successfully, and as rapidly as possible, there is a need to start preparing now. S.K. Lam would like to thank the University of Malaya for their support in providing a grant (HIR J-00000-73554-B27110) HDAC inhibitor for his involvement in dengue activities. Editorial support was provided by Joshua Fink and funded by Sanofi Pasteur. Conflict of interest: Dengue v2V is supported by an unrestricted educational grant from sanofi pasteur. S.K. Lam has received a grant from the University of Malaya on Dengue Mathematical

Modelling, and an honorarium from the University of Malaya for work as a research consultant. S.K. Lam also received an honorarium from Sanofi Pasteur for chairing the 1st Dengue v2V Asia-Pacific Meeting. “
“While much recent scientific and media attention has focused on pandemic influenza, it remains the case that seasonal influenza epidemics represent a major and ongoing threat to public health. WHO estimates that seasonal influenza selleck is responsible for 3,000,000–5,000,000 cases of severe illness and 250,000–500,000 deaths each year [1]. In 2003, the World Health Assembly (WHA) stated, in its resolution on the prevention and control of influenza, that seasonal epidemics cause fatal

complications in up to 1,000,000 people annually [2]. As a result, Rolziracetam WHO and its member countries recognize the role that immunization can play in preventing and reducing this burden, and recommend vaccination for those at risk, in particular the elderly and those with chronic illnesses [1] and [2]. This position is mirrored by the public health policies of many governments [3], with more than 40% of the world’s countries including seasonal influenza vaccination in their national immunization schedules [4]. Recognizing that “many of these deaths could be prevented through increased use, particularly in people at high risk, of existing vaccines, which are safe and highly effective”, the 2003 WHA resolution set a target for those countries with influenza vaccination policies. This called for an increase in vaccine coverage for all people at high risk, and in particular the immunization of at least 50% of the elderly by 2006, rising to 75% by 2010 [2].